Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-24T09:25:26.430Z Has data issue: false hasContentIssue false

Los efectos de la trazodona sobre las perturbaciones del sueño inducidas por brofaromina

Published online by Cambridge University Press:  12 May 2020

P.M.J. Haffmans
Affiliation:
Stichting BBC, location Monsterseweg, La Haya, Holanda
M.S. Vos
Affiliation:
Stichting BBC, location Monsterseweg, La Haya, Holanda
Get access

Resumen

Se compararon los efectos de la trazodona sobre los parámetros subjetivos y objetivos del sueño con los del placebo en un diseño doble ciego en siete pacientes que desarrollaron insomnio durante el tratamiento con el inhibidor selectivo y reversible de la MAO-A brofaromina. La trazodona aumentó significativamente el sueño profundo y alteró la arquitectura del sueño en estos pacientes. Subjetivamente, éstos comunicaron un sueño mejor y más profundo. No se observaron interacciones negativas entre la brofaromina y la trazodona, y los efectos secundarios fueron mínimos. Una dosis baja de trazodona puede ser un agente seguro y efectivo en el tratamiento del insomnio inducido por inhibidores de la MAO.

Type
Comunicación breve
Copyright
Copyright © European Psychiatric Association 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Haffmans PMJ, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry 1999; 14: 167-71.

References

Bibliografía

Kurz, NM, Robinson, DS. Monoamine oxidase inhibitors. In: Georgotas, A, Cráneo, R, eds. Depression and manía: a comprehensive textbook. New York: Elsevier; 1988; 358–71.Google Scholar
Steiger, A, Holsboer, F, Gerken, A. Results of an open clinical trial of brofaromine (CGP II 305 A), a competitive, selective, and short acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 1987; 20: 262–9.CrossRefGoogle Scholar
Nolen, WA, Haffmans, PMJ, Bouvy, PF, Duivenvoorden, HJ. Monoamine oxidase inhibitors in resistant major depression. J Afect Disord 1993; 28: 189–97.CrossRefGoogle ScholarPubMed
Hoencamp, E, Haffmans, PMJ. Brofaromine vs. maprotili-ne plus lithium in treatment resistant depressed out patients. Psychiatry Res 1991; 36: 333–5.CrossRefGoogle Scholar
Hamilton, M. A rating scale for depression. Acta Psychiatr Scand 1989; 73 Suppl 326: 137.Google Scholar
Haffmans, PMJ, Knegtering, R. The selective reversible monoamine oxidase-A inhibitor brofaromine and sleep. J Clin Psychopharmacol 1993; 13: 291–2.CrossRefGoogle Scholar
van Bemmel, AL, van Diest, R, Mevius, GJ. The effeets of REM-sleep suppression on non-REM sleep intensity in depressed patients treated with trazodone. Biol Psychiatry 1991; 29: 620.Google Scholar
Ware, JC, Pittard, JT. Increased deep sleep after trazodone use: a double blind placebo controlled study in healthy young adults. J Clin Psychiatry 1990; 51: 1822.Google ScholarPubMed
Wheatly, D. Trazodone: alternative dose regimens and sleep. Pharmatherapeutica 1984; 3: 607–12.Google Scholar
Scharf, MB, Sacháis, BA. Sleep laboratory evaluation of the effeets and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 1990; 51: 13–7.Google Scholar
Mouret, J, Lemoine, P, Minuit, MP. Effeets of trazodone on the sleep of depressed subjeets - a polygraphic study. Psychopharmacology 1988; 95: 3743.CrossRefGoogle Scholar
Maj, J, Palider, W, Rawlow, A. Trazodone, a central serotonin antagonist and agonist. J Neural Trans 1979; 44: 237–48.CrossRefGoogle ScholarPubMed
Zimmer, B, Daly, F, Benjamín, L. More on combination antidepressant therapy. Arch Gen Psychiatry 1984; 41: 527–8.Google ScholarPubMed
Nierenberg, AA, Keck, PE. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989; 9: 42–5.CrossRefGoogle ScholarPubMed
Jacobson, FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry 1990; 51: 298302.Google Scholar
Fawcett, J, Epstein, P, Fiester, SJ. Symptoms, signs, side-effeets checklist. Psychopharmacol Bull 1987; 23: 322–3.Google Scholar
Mulder, W, Wijnberg, JR, Hollander, JJ. Measurements of subjective sleep quality. 5th European sleep congress. Amsterdam: ESR; 1980.Google Scholar
Rechtschaffen, A, Kales, A. A manual of standardized terminology techniques and scoring system for sleep stages of human subjeets. US Department of Health, Education of Welfare. Bethesda: Neurological Information Network; 1980.Google Scholar
Waldmeier, PC, Baumann, PA, Delini-Stula, A. Characterization of a new, short acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsy-chiatr 1983; 19: 3152.CrossRefGoogle ScholarPubMed